Neurizon Therapeutics Limited

As of June 30, 2025, Neurizon Therapeutics Limited carries a market capitalization of 78.77M, placing it among publicly traded companies globally. Its enterprise value stands at 74.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2025, Neurizon Therapeutics Limited has 500.72M shares outstanding.

These figures are as of June 30, 2025.

As of June 30, 2025, Neurizon Therapeutics Limited maintains a current ratio of 2.84, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Neurizon Therapeutics Limited posted a negative return on equity (ROE) of -254.33, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -214.34, reflecting losses generated across the asset base.

As of the close on October 22, 2026, Neurizon Therapeutics Limited's stock has declined approximately 38.19% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.08.

These figures cover the twelve months ended June 30, 2025. EBITDA reached -18.48M, while operating income came in at -18.48M.

These figures are as of June 30, 2025. Total book value stands at 2.82M, with working capital of 2.82M providing operational flexibility.

These figures cover the twelve months ended June 30, 2025.

These figures cover the twelve months ended June 30, 2025. Total shareholder yield is negative at -11.12, meaning Neurizon Therapeutics Limited raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Neurizon Therapeutics Limited's most recent stock split took place on December 29, 2025 with a 117:119 split ratio.